Evidence Summary

EGCG is the main anticancer catechin in green tea, and the evidence base around EGCG is much larger than most natural compounds used in oncology.

Research Overview

1. Extensive preclinical data across breast, colorectal, lung, prostate, pancreatic, haematologic, oral, and ovarian cancer models

2. Multiple Phase I and Phase II trials in prevention, biomarker, and treatment-support settings

3. Strong epidemiological signals linking regular green tea intake to reduced cancer risk in several cancers

4. Review and meta-analytic literature supports chemopreventive and adjunctive potential

5. Large Phase III oncology treatment trials remain limited

Clinical Application Status

Approved status: Not approved as a cancer drug. Marketed as a dietary supplement and widely consumed in green tea.

Clinical use: Used in integrative oncology for prevention-oriented support, immune and inflammatory modulation, and treatment-support discussions.

Evidence strength: Strong preclinical evidence with early but meaningful human support. Best positioned as adjunctive or chemopreventive rather than monotherapy.

Key Advantages

1. Multi-target activity — affects EGFR, MAPK, PI3K/Akt, mTOR, apoptosis, angiogenesis, and metastasis-related biology

2. Strong epidemiological support — green tea intake has been linked to reduced risk or recurrence signals in several settings

3. Immune relevance — supports interest in NK cells, macrophages, dendritic cells, and tumour-microenvironment signalling

4. Broader health relevance — may also support metabolic, cardiovascular, and antimicrobial goals relevant to cancer patients

5. Combination potential — has preclinical synergy data with selected taxanes, platinum drugs, anthracyclines, and 5-FU

Key Considerations

1. Bioavailability is poor — oral systemic exposure is limited

2. Most human data is not late-stage treatment data — prevention and support remain stronger areas

3. Drug interactions matter — CYP and P-glycoprotein issues need review

4. Bortezomib is a major caution — EGCG may antagonise its proteasome-inhibition mechanism

5. Rare hepatotoxicity has been reported with high-dose extracts — especially concentrated products taken on an empty stomach

Bottom line

EGCG is one of the most credible natural oncology adjuncts from a research-volume perspective. Its best current role is as a complement to standard care, especially in prevention-oriented, inflammatory, metabolic, and pathway-focused contexts.

Key References

Anticancer Molecular Mechanisms of Epigallocatechin-3-Gallate (EGCG)
https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.70735

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
https://pmc.ncbi.nlm.nih.gov/articles/PMC10343677/

Dietary EGCG: State-of-the-Art in Anticancer Research
https://pmc.ncbi.nlm.nih.gov/articles/PMC12844721/